To validate B7H6 as target for CAR T therapy in AML and melanoma, we first analyzed B7H6 expression in patient-derived AML and melanoma samples at the mRNA transcript and cell-surface level in comparison to well-known AML and melanoma cell lines. Here, NCR3LG1 is linked to acute myeloid leukemia.